epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-214, Phase III. Recruiting

Heart failure with reduced ejection fraction

CTS-209 added to standard care in heart failure with reduced ejection fraction. Sponsor: Contoso Pharmaceuticals (fictional), Cardiovascular.

Twenty questions about the protocol, each tied to the research, and what every answer does to recruitment. The answers start as this study's template; change any of them to see what moves.

Contoso Pharmaceuticals (fictional), Phase III, Cardiovascular. Protocol final September 2023. The answers start as this study's protocol; change any of them to see what moves.

All answers match the protocol.

Population and eligibility

How many non-essential exclusions does the protocol carry?

Organ-function limits, brain metastases, prior or concurrent cancers, performance status, and similar criteria that are not needed for safety.

  • Rate ×0.8: Protocol and population: Moderately restrictive eligibility (D13)

Risks: PD-01PD-02EB-04PB-02

Which line of therapy does the study enrol?
  • No effect on the forecast
Is the population an orphan subgroup?

Not used with the rare-disease therapeutic area, which already carries the effect.

  • No effect on the forecast
Does entry require a biomarker, and how common is it?
  • Screening Raises screen failure above the therapeutic-area rate

Risks: PD-12

Does the protocol exclude common comorbidities?
  • No effect on the forecast
Is there an upper age limit?
  • No effect on the forecast

Design

What does the control arm receive?
  • Rate ×0.75: Placebo or no added treatment (D15)

Risks: PD-05PD-17

Is the study blinded?
  • Rate ×0.8: Blinded (D15)

Risks: PD-06EB-03

What is the randomisation ratio?
  • No effect on the forecast
Is there a run-in or a washout longer than four weeks?
  • Screening Some patients are lost before randomisation; the size is not sourced

Risks: PD-09PD-10

Patient burden

How heavy is the visit and procedure schedule?

Compare with similar studies in the same area: number of visits, invasive procedures, questionnaires, overnight stays.

  • No effect on the forecast
Are any visits done remotely or at home?
  • Risk flag Helps distant patients; no recruitment effect is established

Risks: PD-20

Did patients help design the protocol?
  • Rate ×1.1: Yes (D17)

Operations

How settled is the protocol?
  • No effect on the forecast
How many vendors and systems will sites use?
  • Risk flag 22% of sites name the number of technologies and vendors as the biggest driver of complexity

Risks: S-18

What kind of sites will the study mostly use?
  • No effect on the forecast

Risks: S-06

Have most sites worked with the sponsor before?
  • No effect on the forecast

Risks: S-04

Environment

How many competing trials recruit the same patients?
  • Rate ×1: Competing trials: A few

Risks: S-21

Could the standard of care change during the study?
  • Risk flag A new approval can remove the eligible pool or change the control arm until the protocol is amended

Risks: SH-29

Does the study depend on a comparator or backbone drug that has been in short supply?
  • No effect on the forecast

Build a site

A site's rate is built one factor at a time. The questionnaire sets each row, or pick an option to try a different kind of site in every country.

Each country's usual mix of site types, shifted by the site mix answer
Expected mix for mostly repeat sites
Moderately restrictive eligibility ×0.8
A few ×1

Poland recruits fastest per site, at 0.237 a month

Patients randomised per site per month after each factor, by countryDots: filled is evidence-anchored, half-filled takes its direction from evidence, hollow is an assumption, hatched combines several; United States highlighted

Source: epiClinical evidence library; each factor's basis and source are in the rows beside the chart.

Shaded: Industry Phase III median, 0.4. Median 0.4 patients per site per month (interquartile range 0.2 to 0.6) in completed industry Phase III trials, 2016 to 2019 (PLOS ONE 2022; D01).

Shaded: UK public trials median, 0.92 to 0.95. Median 0.92 to 0.95 patients per centre per month in UK publicly funded trials (Walters 2017; Jacques 2022; D01).

Show data
Patients randomised per site per month after each factor, by country
FactorUnited StatesUnited KingdomSpainPolandTurkeyIndia
Therapeutic area0.3000.3000.3000.3000.3000.300
Country0.2250.2550.3000.4200.3000.330
Site type0.2220.2490.2930.4320.2890.314
Track record0.2180.2440.2870.4230.2840.308
Protocol and population0.1740.1950.2300.3380.2270.246
Patient acceptability0.1220.1360.1610.2370.1590.173
Competing trials0.1220.1360.1610.2370.1590.173

What this design does to the sites needed

To finish by March 2027 with 85% confidence, this design needs about 197 sites, the same as the protocol as written.

CountryPer site per month, protocol as writtenWith this designChangeSites needed, protocolWith this design
United States0.1220.122–88
United Kingdom0.1360.136–4444
Spain0.1610.161–7171
Poland0.2370.237–4141
Turkey0.1590.159–1818
India0.1730.173–1515

Forecast this design

Risks these answers switch on

Open a risk to see its effect, what helped, what did not and the sources. Grade A is the strongest evidence and D the weakest.

Protocol and design

PD-01Restrictive eligibility criteria (organ function, brain metastases, prior or concurrent malignancy, HIV, laboratory thresholds, performance status) Grade A
Effect
Negative; eligible pool ×0.48 to 0.53 against broadened criteria, with the hazard ratio unchanged or better.
What helped
ASCO-Friends modernised criteria and the FDA 2020 to 2026 guidances; data-driven criteria; adoption of 54 to 93% by criterion in NCI CTEP protocols.
What did not
Laboratory and washout exclusions carried forward unchanged across phases and years.
Sources
Harvey 2021; Liu 2021; Kim 2017 and 20212; Unger 2019
PD-02Number of eligibility criteria and complexity growth Grade B
Effect
Negative; more criteria independently associated with poor accrual (p = 0.013); complex trials randomise 59% of screened against about 75%.
What helped
Upstream protocol feasibility review and benchmarking against Tufts norms.
What did not
not found
Sources
Carlisle 2015; Getz 2014; Getz 2023
EB-04Restrictive eligibility criteria and protocol complexity Grade B
Effect
Negative; more eligibility criteria associated with accrual failure (p=0.013), 21.5% of cancer patients ineligible for an available trial, procedure counts rising 6.5 to 10.5% a year, and tissue sample required OR 1.26 with a CI including 1.
What helped
CTTI framework recommends limiting complexity and realistic eligibility (not quantified).
What did not
not found
Sources
Carlisle 2015; Unger 2019; Getz 2008; Getz 2018; Bennette 2016
PB-02Eligibility criteria exclude patients (comorbidity, age, performance status, language) Grade A
Effect
21.5% (10.9 to 34.6) of patients with an open trial are ineligible; any comorbidity cuts participation odds to 0.76; 81.3% of high-impact RCTs exclude common conditions; 19% of US trials require English.
What helped
Broadening criteria: dropping the comorbidity restrictions ASCO recommends removing could add up to 6,317 registrations a year; translation widens the pool.
What did not
not found
Sources
Unger 2019 JNCI; Unger 2019 JAMA Oncol; Van Spall 2007; Muthukumar 2021
PD-12Biomarker-selected population with low marker prevalence Grade B
Effect
Negative; 37.6% actionable and 17.8% assigned in NCI-MATCH; 39 to 70% amyloid-negative at screening; MASH screen failure 56%.
What helped
Central screening at scale (1,117 sites); EHR and registry pre-screening.
What did not
not found
Sources
Flaherty 2020; Sevigny 2016; Sperling 2020; Souza 2025
PD-05Placebo or no-added-treatment control arm Grade B
Effect
Negative; willingness 30% against 39%; acceptance 60.5% against 80.6%.
What helped
All-active arms; add-on designs; equipoise-focused recruiter training through the QRI.
What did not
not found
Sources
Welton 1999; Jenkins 2000; Mills 2006; Uzzan 2023
PD-17Active comparator (against placebo) in registry data Grade B
Effect
Negative association only; poor accrual 23% against 16%.
What helped
not found
What did not
not found
Sources
Carlisle 2015
PD-06Blinded placebo-controlled against open design Grade A
Effect
Negative for blinding; an open design adds 10 percentage points (95% CI 7 to 13), high certainty.
What helped
Open or PROBE design where scientifically acceptable.
What did not
User-tested information leaflets added 1 point, no effect.
Sources
Treweek 2018
EB-03Blinded placebo-controlled design instead of open-label Grade A
Effect
Open design recruits 10 percentage points more of eligible patients (95% CI 7 to 13); at trial level active-comparator trials failed accrual more often than placebo trials (23% against 16%), and per-centre rates did not differ significantly.
What helped
Open-label or pragmatic design where scientifically acceptable (high certainty).
What did not
not found
Sources
Treweek 2018; Carlisle 2015; Walters 2017; Jacques 2022
PD-09Washout periods and concomitant-medication exclusions Grade C
Effect
Negative and qualitative; IBD patients deterred; criteria often arbitrary.
What helped
Remove arbitrary washouts, as the FDA final guidance of July 2026 requires.
What did not
not found
Sources
Harvey 2021 washout group; Liu 2021; Uzzan 2023
PD-10Run-in period before randomisation Grade C
Effect
Negative for randomised yield; narrows the population and overstates benefit.
What helped
Use only where there is a scientific need.
What did not
not found
Sources
Pablos-Méndez 1998
PD-20Decentralised elements Grade C
Effect
Unclear; modelled value only; sites split on whether they add or remove burden.
What helped
Hybrid elements for follow-up visits.
What did not
A fully remote trial under-recruited despite a very large outreach funnel.
Sources
FDA 2024; DiMasi 2023; Nassif 2023; Florez 2024
SH-29Standard-of-care change Grade B
Effect
11% of non-data terminations on ClinicalTrials.gov came from external information or product withdrawal.
What helped
Protocol amendment of the comparator.
What did not
not found
Sources
Williams et al. 2015

Site

S-06Site type: activation speed Grade A
Effect
Negative for academic and hospital sites: median 8.1 months versus 4.4 months for independent sites; 9% versus 54% start within 60 days; 21%, 34%, and 80% within 60 days for AMCs, hospital systems, and investigative sites.
What helped
Standardised start-up workflow with a site navigator (133 versus 277 days). Master contracts. UK National Contract Value Review (305 to 194 days).
What did not
Sequential review layers. Pre-activation amendments, which add 4 to 6 weeks each.
Sources
Smith (WCG) 2024; Advarra 2020; WCG 2025; Dilts and Sandler 2006
S-04Past performance as a predictor Grade B
Effect
Positive but modest: Spearman 0.13 to 0.16 for historical rate alone and 0.37 to 0.46 with patient-volume data; well-performing sites have a 70% higher chance of out-performing; trial-manager predictions reach 82% sensitivity but 32% specificity.
What helped
Combine historical rate with real-world patient volume, referral flow, and research experience. Guided prediction forms with red flags.
What did not
Historical performance alone. Unguided judgement after the initiation visit.
Sources
Getz 2011; Hulstaert 2024; Bruhn 2019; Yang 2018; Ninh 2026
S-21Competing trials Grade B
Effect
Negative when the eligible pool is scarce: OR 1.88 (1.32 to 2.68) for low accrual per competing trial per 10,000 eligible patients per year; no effect when the pool is large; 3,042 immuno-oncology trials sought 577,076 patients.
What helped
Redirect referrals to non-overlapping sites and re-engage the PI (anecdotal). Choose indications and regions with slack.
What did not
Adding sites into the same saturated pool.
Sources
Bennette 2016; Hutchinson 2022; Tang 2018; ClinOops 2026

Sponsor, CRO and model

S-18Technology burden Grade B
Effect
Negative on site time, unquantified for enrolment: 60% of sites use 20 or more systems daily, about 10 to 12 applications per site in 2015, 46% say too many separate technologies and 74% cite login tracking (2020), 40% of sites spend 5 to 15 hours per month per study on unpaid training, and 19% rank sponsor technology a top challenge.
What helped
Accept site-preferred systems. Consistent technology across a sponsor's studies. Paid training.
What did not
not found
Sources
WCG 2024; SCRS 2023 Site Landscape; Bechtel 2024; Florence 2024; SCRS 2020